(Q33895386)

29 July 2017

1 reference

title

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation (English)

1 reference

29 July 2017

1 reference

Baron F

1

1 reference

PubMed ID

10773061

29 July 2017

Beguin Y

series ordinal

2

1 reference

PubMed ID

10773061

29 July 2017

language of work or name

1 reference

1 April 2000

1 reference

29 July 2017

1 reference

29 July 2017

40

1 reference

29 July 2017

4

1 reference

29 July 2017

468-476

1 reference

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

29 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Mechanisms of the graft-versus-leukemia reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Natural killer cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Gene transfer applied to the modulation of alloreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2000.40040468.X

10.1046/J.1537-2995.2000.40040468.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10773061